Clinical Trials Logo

Clinical Trial Summary

AIMS & OBJECTIVES To evaluate the effectiveness of administering of Carica folia mother tincture to healthy individual's Platelet count.

Sample Details:- Students, Doctors and non-teaching staffs of Father Muller Homoeopathic Medical College are taken up for the study. A minimum of 60 persons will be selected and will be divided into two groups, Control & Experiment by lottery method.

Voluntary participation in the study is expected. 30 persons in each group. One group will receive Carica folia mother tincture and other group will receive placebo.

Complete Blood count including platelet count will be measured for all 60 subjects before commencing the study.

The drug namely Carica Folia mother tincture will be procured from Father Muller Homoeopathic Pharmaceutical Division which compiles with the standards of Homoeopathic Pharmacopeia of India.

Daily dosage -30 drops of Carica Folia mother tincture in 30 ml of distilled water morning and night for 3days.

On 4th day complete blood count including platelet count will be estimated for all 60 subjects.

Research Methodology and Statistics:

Pre &Post with Control Design is done. Data from the sample is collected and is subjected to Paired 't' test and unpaired 't' test.

HYPOTHESIS:-

Null hypothesis:

No significant changes in complete blood count and platelet count before and after the intervention.

Alternate hypothesis:

There is significant variation in complete blood count and platelet count before and the intervention.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02016027
Study type Interventional
Source Fr Muller Homoeopathic Medical College
Contact
Status Enrolling by invitation
Phase Phase 1
Start date September 2013
Completion date December 2013

See also
  Status Clinical Trial Phase
Completed NCT05321264 - Educational Intervention to Promote Control Behaviors and Prevention of Dengue N/A
Completed NCT01436396 - Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Phase 3
Completed NCT01391819 - Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children N/A
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02833584 - Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults N/A
Completed NCT02433652 - Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 Phase 1
Completed NCT01477671 - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children N/A
Recruiting NCT00377754 - Prospective Study of Infant Dengue N/A
Recruiting NCT05919277 - A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
Recruiting NCT04582474 - Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso N/A
Completed NCT01983553 - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed NCT03803618 - Dengue Effectiveness Study in the Philippines
Active, not recruiting NCT05967455 - Homologous Re-infection With Dengue 1 or Dengue 3 Phase 1
Completed NCT03631719 - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Recruiting NCT02606019 - The Use of Biomarkers in Predicting Dengue Outcome N/A
Completed NCT02372175 - Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain Phase 1
Active, not recruiting NCT01696422 - Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine Phase 2
Completed NCT00993447 - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Phase 2
Completed NCT00375726 - Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults Phase 1
Recruiting NCT05153018 - Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu N/A